Review ArticleClinical Review

Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?

Alan G. Kaplan
The Journal of the American Board of Family Medicine March 2020, 33 (2) 289-302; DOI: https://doi.org/10.3122/jabfm.2020.02.190227

References

  1. 1.↵
    Global initiative for asthma (GINA). Global strategy for asthma management and prevention, 2019. Available at https://ginasthma.org/gina-reports/. Accessed September 12, 2019.
  2. 2.↵
    1. Ejiofor S,
    2. Turner AM
    . Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med 2013;7:17–34.
    OpenUrl
  3. 3.↵
    1. Barnes PJ
    . Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80:89–95.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Kaplan AG
    . Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis 2015;10:2535–48.
    OpenUrl
  5. 5.↵
    1. Barnes PJ
    . Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8:183–92.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Chalmers JD,
    2. Poole C,
    3. Webster S,
    4. Tebboth A,
    5. Dickinson S,
    6. Gayle A
    . Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respir Res 2018;19:63.
    OpenUrl
  7. 7.↵
    1. Price D,
    2. West D,
    3. Brusselle G,
    4. et al
    . Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014;9:889–904.
    OpenUrlPubMed
  8. 8.↵
    1. Price D,
    2. Miravitlles M,
    3. Pavord I,
    4. et al
    . First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med 2016;26:16061.
    OpenUrl
  9. 9.↵
    1. Petite SE
    . Characterization of chronic obstructive pulmonary disease prescribing patterns in the United States. Pulm Pharmacol Ther 2018;49:119–22.
    OpenUrl
  10. 10.↵
    Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020. Available at https://goldcopd.org/. Accessed February 4, 2020.
  11. 11.↵
    1. Kew KM,
    2. Seniukovich A
    . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;CD010115.
  12. 12.↵
    1. Carlin BW,
    2. Schuldheisz SK,
    3. Noth I,
    4. Criner GJ
    . Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. Postgrad Med 2017;129:725–33.
    OpenUrl
  13. 13.↵
    1. Yang IA,
    2. Clarke MS,
    3. Sim EH,
    4. Fong KM
    . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;CD002991.
  14. 14.↵
    1. Nannini LJ,
    2. Poole P,
    3. Milan SJ,
    4. Kesterton A
    . Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;CD006826.
  15. 15.↵
    1. Kaplan A
    . Update: what is new in COPD in 2018? Can Geriatrics Soc 2018;7:2. Available at http://canadiangeriatrics.ca/2018/01/update-what-is-new-in-copd-in-2018/. Accessed May 17, 2019.
    OpenUrl
  16. 16.↵
    1. Bateman ED,
    2. Ferguson GT,
    3. Barnes N,
    4. et al
    . Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–94.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Wurst KE,
    2. St Laurent S,
    3. Hinds D,
    4. Davis KJ
    . Disease burden of patients with asthma/COPD overlap in a US claims database: impact of ICD-9 coding-based definitions. COPD 2017;14:200–9.
    OpenUrl
  18. 18.↵
    1. Divo M,
    2. Cote C,
    3. de Torres JP,
    4. et al
    . Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155–61.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Bourbeau J,
    2. Bhutani M,
    3. Hernandez P,
    4. et al
    . CTS position statement: pharmacotherapy in patients with COPD—An update. Can J Resp Crit Care Sleep Med 2017;1:222–41.
    OpenUrl
  20. 20.↵
    1. Suissa S,
    2. Barnes PJ
    . Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009;34:13–6.
    OpenUrlFREE Full Text
  21. 21.↵
    1. Alsaeedi A,
    2. Sin DD,
    3. McAlister FA
    . The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59–65.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Ernst P,
    2. Saad N,
    3. Suissa S
    . Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45:525–37.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Spencer S,
    2. Evans DJ,
    3. Karner C,
    4. Cates CJ
    . Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;CD007033.
  24. 24.↵
    1. Nannini LJ,
    2. Lasserson TJ,
    3. Poole P
    . Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;CD006829.
  25. 25.↵
    1. Vogelmeier CF,
    2. Bateman ED,
    3. Pallante J,
    4. et al
    . Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51–60.
    OpenUrl
  26. 26.↵
    1. Zhong N,
    2. Wang C,
    3. Zhou X,
    4. et al
    . LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015;10:1015–26.
    OpenUrlPubMed
  27. 27.↵
    1. Roche N,
    2. Chapman KR,
    3. Claus F,
    4. et al
    . Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med 2017;195:1189–97.
    OpenUrl
  28. 28.↵
    1. Vogelmeier CF,
    2. Chapman KR,
    3. Miravitlles M,
    4. et al
    . Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. Int J Chron Obstruct Pulmon Dis 2018;13:1125–34.
    OpenUrl
  29. 29.↵
    1. Wedzicha JA,
    2. Banerji D,
    3. Chapman KR,
    4. et al
    . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222–34.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Vestbo J,
    2. Vogelmeier C,
    3. Small M,
    4. Higgins V
    . Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med 2014;108:729–36.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Nishi SPE,
    2. Maslonka M,
    3. Zhang W,
    4. Kuo YF,
    5. Sharma G
    . Pattern and adherence to maintenance medication use in medicare beneficiaries with chronic obstructive pulmonary disease: 2008–2013. Chronic Obstr Pulm Dis 2018;5:16–26.
    OpenUrl
  32. 32.↵
    1. Crim C,
    2. Dransfield MT,
    3. Bourbeau J,
    4. et al
    . Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12:27–34.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lee MC,
    2. Lee CH,
    3. Chien SC,
    4. et al
    . Inhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a Nationwide Cohort Study. Medicine 2015;94:e1723.
    OpenUrl
  34. 34.↵
    1. Yawn BP,
    2. Suissa S,
    3. Rossi A
    . Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med 2016;26:16068.
    OpenUrl
  35. 35.↵
    1. Pavord ID,
    2. Lettis S,
    3. Anzueto A,
    4. Barnes N
    . Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016;4:731–41.
    OpenUrl
  36. 36.↵
    1. Suissa S,
    2. Coulombe J,
    3. Ernst P
    . Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015;148:1177–83.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Crim C,
    2. Calverley PMA,
    3. Anderson JA,
    4. et al
    . Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir Med 2017;131:27–34.
    OpenUrl
  38. 38.↵
    1. Vestbo J,
    2. Anderson JA,
    3. Brook RD,
    4. et al
    . Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817–26.
    OpenUrlPubMed
  39. 39.↵
    1. Gonzalez AV,
    2. Coulombe J,
    3. Ernst P,
    4. Suissa S
    . Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest 2018;153:321–8.
    OpenUrl
  40. 40.↵
    1. Price DB,
    2. Russell R,
    3. Mares R,
    4. et al
    . Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PloS One 2016;11:e0162903.
    OpenUrl
  41. 41.↵
    1. Sannarangappa V,
    2. Jalleh R
    . Inhaled corticosteroids and secondary adrenal insufficiency. Open Respir Med J 2014;8:93–100.
    OpenUrl
  42. 42.↵
    1. Brode SK,
    2. Campitelli MA,
    3. Kwong JC,
    4. et al
    . The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 2017;50:1700037.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Beeh KM,
    2. Derom E,
    3. Echave-Sustaeta J,
    4. et al
    . The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis 2016;11:193–205.
    OpenUrl
  44. 44.↵
    1. Donohue J,
    2. Worsley S,
    3. Zhu C,
    4. Hardaker L,
    5. Church A
    . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015;109:870–81.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Hoshino M,
    2. Ohtawa J,
    3. Akitsu K
    . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair® in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015;30:128–33.
    OpenUrl
  46. 46.↵
    1. Magnussen H,
    2. Paggiaro P,
    3. Schmidt H,
    4. Kesten S,
    5. Metzdorf N,
    6. Maltais F
    . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med 2012;106:1413–20.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Singh D,
    2. Worsley S,
    3. Zhu CQ,
    4. Hardaker L,
    5. Church A
    . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med 2015;15:91.
    OpenUrl
  48. 48.↵
    1. Vogelmeier C,
    2. Paggiaro PL,
    3. Dorca J,
    4. et al
    . Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J 2016;48:1030–9.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Goto A,
    2. Shibata Y,
    3. Ota E,
    4. et al
    . Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017;2:CD012066.
    OpenUrlPubMed
  50. 50.↵
    1. Frith PA,
    2. Ashmawi S,
    3. Krishnamurthy S,
    4. et al
    . Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology 2018;23:1152–9.
    OpenUrl
  51. 51.↵
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N,
    4. et al
    . Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378:1671–80.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Suissa S,
    2. Drazen JM
    . Making sense of triple inhaled therapy for COPD. N Engl J Med 2018;378:1723–4.
    OpenUrl
  53. 53.↵
    1. Ishiura Y,
    2. Fujimura M,
    3. Shiba Y,
    4. Ohkura N,
    5. Hara J,
    6. Kasahara K
    . A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome. Pulm Pharmacol Ther 2015;35:28–33.
    OpenUrl
  54. 54.↵
    1. Lee SY,
    2. Park HY,
    3. Kim EK,
    4. et al
    . Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2016;11:2797–803.
    OpenUrl
  55. 55.↵
    1. Siva R,
    2. Green RH,
    3. Brightling CE,
    4. et al
    . Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906–13.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Pascoe S,
    2. Locantore N,
    3. Dransfield MT,
    4. Barnes NC,
    5. Pavord ID
    . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435–42.
    OpenUrl
  57. 57.↵
    1. Siddiqui SH,
    2. Guasconi A,
    3. Vestbo J,
    4. et al
    . Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523–5.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Zysman M,
    2. Deslee G,
    3. Caillaud D,
    4. et al
    . Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017;12:1819–24.
    OpenUrl
  59. 59.↵
    1. Casanova C,
    2. Celli BR,
    3. de-Torres JP,
    4. et al
    . Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017;50:1701162.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Bafadhel M,
    2. McKenna S,
    3. Terry S,
    4. et al
    . Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48–55.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Turato G,
    2. Semenzato U,
    3. Bazzan E,
    4. et al
    . Blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;197:1216–9.
    OpenUrl
  62. 62.↵
    1. Harlander M,
    2. Barrecheguren M,
    3. Turel M,
    4. Miravitlles M
    . Should patients switched from D to B in the GOLD 2017 classification be discontinued from inhaled corticosteroids? COPD 2017;14:465–8.
    OpenUrl
  63. 63.↵
    1. Tsiligianni I,
    2. Kaplan AG
    . Are blood eosinophils a prime-time biomarker for COPD management decisions? Int J Chron Obstruct Pulmon Dis 2018;13:1889–91.
    OpenUrl
  64. 64.↵
    1. Frith PA,
    2. Thompson PJ,
    3. Ratnavadivel R,
    4. et al
    . Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 2015;70:519–27.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Lipson DA,
    2. Barnacle H,
    3. Birk R,
    4. et al
    . FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:438–46.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Siler TM,
    2. Kerwin E,
    3. Sousa AR,
    4. Donald A,
    5. Ali R,
    6. Church A
    . Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med 2015;109:1155–63.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Singh D,
    2. Papi A,
    3. Corradi M,
    4. et al
    . Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963–73.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Sousa AR,
    2. Riley JH,
    3. Church A,
    4. Zhu CQ,
    5. Punekar Y,
    6. Fahy W
    . The effect of umeclidinium added to inhaled corticosteroid/long-acting beta2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med 2016;26:16031.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Singh D,
    2. Corradi M,
    3. Spinola M,
    4. et al
    . Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis 2017;12:2917–28.
    OpenUrl
  70. 70.↵
    1. Vestbo J,
    2. Papi A,
    3. Corradi M,
    4. et al
    . Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919–29.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Papi A,
    2. Vestbo J,
    3. Fabbri L,
    4. et al
    . Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076–84.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Ferguson GT,
    2. Rabe KF,
    3. Martinez FJ,
    4. et al
    . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747–58.
    OpenUrl
  73. 73.↵
    1. Rossi A,
    2. Molen T,
    3. Olmo R,
    4. et al
    . INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 2014;44:1548–56.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Rossi A,
    2. Guerriero M,
    3. Corrado A
    . Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014;15:77.
    OpenUrlPubMed
  75. 75.↵
    1. Magnussen H,
    2. Diss B,
    3. Rodriguez-Roisin R,
    4. et al
    . Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285–94.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Calverley PM,
    2. Tetzlaff K,
    3. Vogelmeier C,
    4. et al
    . Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:1219–21.
    OpenUrl
  77. 77.↵
    1. Watz H,
    2. Tetzlaff K,
    3. Wouters EFM,
    4. et al
    . Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390–8.
    OpenUrl
  78. 78.↵
    1. Chapman KR,
    2. Hurst JR,
    3. Frent SM,
    4. et al
    . Long-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:329–39.
    OpenUrl
  79. 79.↵
    1. Vogelmeier C,
    2. Worth H,
    3. Buhl R,
    4. Criée CP,
    5. et al
    . “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis 2017;12:487–94.
    OpenUrl
  80. 80.↵
    1. Calverley PM,
    2. Tetzlaff K,
    3. Dusser D,
    4. et al
    . Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis 2017;12:3391–405.
    OpenUrl
  81. 81.↵
    1. Kunz LI,
    2. Hacken NHT,
    3. Lapperre TS,
    4. et al
    . Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. Eur Respir J 2017;49.
  82. 82.↵
    1. Calzetta L,
    2. Matera MG,
    3. Braido F,
    4. et al
    . Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther 2017;45:148–58.
    OpenUrl
  83. 83.↵
    1. Kaplan AG,
    2. Román-Rodríguez M,
    3. Price DB,
    4. Tsiligianni I
    . Appropriate use and withdrawal of inhaled corticosteroids in patients with COPD. IPCRG desktop helper no 6. March 2017. Available at https://www.theipcrg.org/download/attachments/35390454/Summary%20of%20Evidence%20v.2.pdf?version=1&modificationDate=1532348072000&api=v2. Accessed May 17, 2018.
  84. 84.
    1. Lim HS,
    2. Choi SM,
    3. Lee J,
    4. et al
    . Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol 2014;113:652–7.
    OpenUrlCrossRefPubMed
  85. 85.
    1. Chapman KR,
    2. Hurst J,
    3. Frent S,
    4. et al
    . Withdrawal of inhaled corticosteroids from COPD patients inhaling long-term triple therapy: the SUNSET Study. Am J Respir Crit Care Med 2018;197:A1009.
    OpenUrl
  86. 86.
    1. Halpin DMG,
    2. Birk R,
    3. Brealey N,
    4. et al
    . Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res 2018;4.
  87. 87.
    1. Papi A,
    2. Kostikas K,
    3. Wedzicha JA,
    4. et al
    . Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med 2018;197:1223–6.
    OpenUrl
  88. 88.
    1. Anzueto AR,
    2. Kostikas K,
    3. Mezzi K,
    4. et al
    . Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res 2018;19:121.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords